Inflammatory bowel diseases (IBDs),including Crohn’sdisease and ulcerative colitis are chronic inflammatorydisorders of gastrointestinal tract.Although the etiology isincompletely understood,initiation and aggravation of theinflammatory process seem to be due to a massive localmucosal immune response.Interleukin-10 (IL-10) is aregulatory cytokine which inhibits both antigen presentationand subsequent pro-inflammatory cytokine release,and itis proposed as a potent anti-inflammatory biological therapyin chronic IBD.Many methods of IL-10 as a treatment forIBD have been published.The new strategies of IL-10treatment,including recombinant IL-10,the use of geneticallymodified bacteria,gelatine microsphere containing IL-10,adenoviral vectors encoding IL-10 and combining regulatoryT cells are discussed in this review.The advantages anddisadvantages of these IL-10 therapies are summarized.Although most results of recombinant IL-10 therapies aredisappointing in clinical testing because of lacking efficacyor side effects,therapeutic strategies utilizing gene therapymay enhance mucosal delivery and increase therapeuticresponse.Novel IL-10-related cytokines,including IL-19,IL-20,IL-22,IL-24,IL-26,IL-28 and IL-29,are involved inregulation of inflammatory and immune responses.The useof IL-10 and IL-10-related cytokines will provide new insightsinto cell-based and gene-based treatment against IBD innear future. Inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Although the etiology is fully reconstructed, initiation and aggravation of the inflammatory process seems to be due to a massive local mucosal immune response. Interleukin-10 (IL- 10) is aregulatory cytokine which inhibits both antigen presentation and subsequent pro-inflammatory cytokine release, and itis proposed as a potent anti-inflammatory biological therapy in chronic IBD. Many methods of IL-10 as a treatment for IBD have been published. The new strategies of IL -10treatment, including recombinant IL-10, the use of genetically modified bacteria, gelatine microsphere containing IL-10, adenoviral vectors encoding IL-10 and combining regulatory T cells are discussed in this review. These advantages and advantages of these IL-10 therapies are summarized. Although most results of recombinant IL-10 therapies aredisappointing in clinical testing because of lackin g efficacyor side effects, therapeutic strategies utilizing gene therapy enhance enhances mucosal delivery and increase therapeutic response. Novel levels of IL-10-related cytokines including IL-19, IL-20, IL-22, IL- 24, IL-29, are involved in the development of inflammatory and immune responses. The use of IL-10 and IL-10-related cytokines will provide new insightsinto cell-based and gene-based treatment against IBD innear future.